Psychedelics Now Virtual Conference

December 8th, 2021

Hosted By:

Panel 1

“The FDA and Psychedelics – Where are we Today?”

10AM-11AM PT

Panel 2

“Ketamine and the Insurance Quagmire”

11:30AM-12:30PM PT

Panel 3

“Road to Monetization”




Host - Paul Rosen

Executive Chairman, Psychedelics Go

Paul Rosen is a noted career entrepreneur, management consultant and public speaker.
Paul was a co-founder of PharmaCan Capital Corp. doing business as The Cronos Group (NASDAQ: CRON; TSX: CRON) and served as its first President and CEO. Paul has held board positions with a number of publicly traded cannabis companies, and serves as the Executive Chairman of Global Go, a leading advisory focused on the global regulated cannabis and psychedelic industries. Paul currently serves as interim CEO of 1933 Industries, a Las Vegas based vertically integrated cannabis operator. Paul is also a Director at Delic Holdings Inc. (DELC:CNSX), a leader in the nascent and growing space of psychedelic wellness.

Panel 1 - "The FDA and Psychedelics - Where are we Today?"

Join us for a discussion on the state of federal legalization today and the current regulatory challenges operators face in the psychedelics industry.

Moderator, Melissa Lavasani

Founder & Executive Director, Plant Medicine Coalition

Melissa Lavasani is the Founder and Executive Director of Plant Medicine Coalition. Prior to founding the Plant Medicine Coalition, Melissa was the proposer of Washington DC’s successful 2020 ballot measure Initiative 81, the Entheogenic Plant and Fungus Policy Act. Inspired by her own experience of using psychedelics to heal her severe postpartum depression, Melissa led the Decriminalize Nature DC campaign to the largest ballot initiative victory in the history of our nation’s capital. Through Plant Medicine Coalition, Melissa continues the work of implementation of Initiative 81 and DC’s new law enforcement priorities regarding plant medicines as well as advocate for laws that support healing with psychedelics at the federal and state level. Melissa is also a Founding Member of the Psychedelics and Healing Initiative at the Global Wellness Institute.

Melissa has a Bachelor’s degree in Economics from Macalester College, a Masters degree in Management from the University of Denver, and a Masters in Public Policy from George Mason University. Born in Washington, DC to Iranian immigrants, Melissa currently lives in Northeast DC with her husband Daniel, daughter Lola (7), son Ramsey (4), and their rescue pitbull, Gus.

Panelist, Jon Dennis

Principal, Psychedelics Go

Jon Dennis is a lawyer and entrepreneur in the psychedelics ecosystem. His interests include psychedelic retreat and wellness centers, psychedelic hospitality, religious use of plant and fungi medicines, equity in psychedelics, education and training programs, cultivation and production, ketamine clinics, and Oregon’s novel Psilocybin Services Act (also known as Measure 109). Jon assists early movers in the psychedelics space with decision-making in light of the current and emerging opportunities in the U.S. and international markets, with particular focus on psilocybin businesses in Oregon. Jon has taken the North Start Ethics Pledge and was drawn to this work by the conviction that psychedelics possess the potential to accelerate our individual and collective shifts away from self-destructive paradigms. Prior to joining Psychedelics Go, Jon worked as a civil litigator and managed a nonprofit law office giving free legal assistance to people living in poverty. He began working in psychedelics while volunteering for the campaign to legalize psilocybin therapy in Oregon. He lives in Ontario, Oregon, which boasts the highest number of cannabis dispensaries per capita in the United States. Jon has a BA in Religious Studies from the University of Kansas and a law degree from Lewis & Clark Law School.

Panelist, Jeeshan Chowdhury, MD, PhD

Founder & CEO, Journey Colab

Dr. Jeeshan Chowdhury is an MD/PhD and studied at Oxford as a Rhodes Scholar. He is a seasoned entrepreneur, having founded and sold ListRunner, a digital tool for frontline clinical teams. Trained in psychedelic-assisted therapy through CIIS, Dr. Chowdhury is now bringing his expertise to Journey Colab as Founder and CEO.

Panelist, Ahmad Doroudian

CEO & Director, BetterLife Pharma, Inc.

Ahmad Doroudian is an entrepreneur and businessperson who founded Merus Labs International, Inc., BetterLife Pharma, Inc., Silvio Ventures, Inc. and Pangeo (USA) Corp. and who has been the head of 10 different companies. Presently, Ahmad Doroudian occupies the position of Chief Executive Officer & Director at BetterLife Pharma, Inc. and Chief Executive Officer & Director at Altum Pharmaceuticals, Inc. (a subsidiary of BetterLife Pharma, Inc.). He is also on the board of 6708595 Canada, Inc. In his past career he held the position of Chairman & Secretary at BetterLife Pharma, Inc., President, Chief Executive Officer & Director at Vansen Pharma, Inc., President for Rayan Pharma, Inc., Operations Manager at Novapharm Ltd, President, Chief Executive Officer & Director at Merus Labs, Inc., Vice Chairman of Merus Labs International, Inc., Chief Executive Officer at Pangeo (USA) Corp., President, Chief Executive Officer & Director at Merus Labs International, Inc., Chief Executive Officer at ABF Pharmaceutical Services GmbH and Vice Chairman at Silvio Ventures, Inc. He received a doctorate, an undergraduate degree and a graduate degree from the University of British Columbia.

Panelist, Hannah McLane, MD, MA, MPH

Founder, SoundMind

◦ Hannah McLane, MD, MA, MPH is a physician, psychotherapist, and executive function coach in Philadelphia. She completed Brown Medical School in Rhode Island, attended residency at the University of Pennsylvania (Neurology and Occupational Medicine), and holds Master’s degrees in Public Health (Harvard) and Speech Pathology (Temple University). In 2010 she founded a nonprofit, the Soundmind Project, and currently also conducts research at the VA Medical Center in Philadelphia which focuses on cognitive diversity, PTSD, and emerging alternative therapies for mental health issues.
Dr. McLane offers individual psychotherapy using a psychodynamic approach, and Executive Function Coaching with a specialization in ADHD and dyslexia. She also offers sleep therapy with a focus on the effects of adverse past experiences, PTSD, and circadian rhythms on sleep quality.

Panel 2 - "Ketamine and the Insurance Quagmire"

Join us for a discussion where we will address the lack of insurance coverage for new variations of ketamine treatments despite the S-Ketamine’s (Spravato) FDA approval for severe depression.

Moderator, Los Arias

Principal, Psychedelics Go

Carlos “Los” Arias is Co-Founder & Co-CEO at Green Horizons; Co-Founder & Principal at Desert Horizon; and a Principal at RiverRock. Arias’s mission in life is to impact the planet as an advocate for natural medicine. Green Horizons is a scaled cultivation concern with 1,000,000 sq. ft. in development in Coachella, California. Desert Horizon is a premier indoor craft facility, with 21,000 sq. ft. of operations in Cathedral City, California. RiverRock is one of Colorado’s founding regulated cannabis companies, located in the Greater Denver area. Arias is a graduate of Southwestern University School of Law in Los Angeles, and moreover has trained with multiple plant and amphibian medicine modalities

Panelist, Jack Swain

Head of Clinical Operations, MindBloom

Jack Swain is Head of Clinical Operations at Mindbloom, a mental health and wellbeing company focused on psychedelic therapy. Before joining Mindbloom, Jack Swain was a healthcare consultant at The Chartis Group, where he worked with the Cleveland Clinic and Michigan Medicine.

Panelist, Carl J. Bonnett

Founder & Medical Director, Klarisana

Founder & Medical Director of Klarisana. Klarisana offers ketamine therapy to patients suffering from treatment-resistant depression, PTSD, and various chronic pain syndromes. Centers in Colorado, New Mexico, and Texas. Board Certified (ABEM) Emergency Physician. Graduated from Denver Health in 2005. Denver Health EMS/Disaster Medicine fellowship 2006. Retired from the Colorado Army National Guard. Four deployments in support of OIF/OEF. Awarded the Combat Medical Badge in 2007 for service with the 41st Brigade Combat team in Afghanistan.

Panelist, Carlene MacMillan

CEO & Co-Founder, Brooklyn Minds

Carlene MacMillan, who proudly leads Brooklyn Minds as CEO, started this practice with an ambitious goal: to provide care for clients who find themselves struggling at the margins of mental healthcare. As the practice grows, Dr. MacMillan has worked tirelessly to cultivate a team of clinicians and support staff who are aligned with this bold vision in order to ensure we continually meet our communities’ needs where they stand. Dr. MacMillan is versatile in her approach, using a variety of evidence-based treatments for personality disorders in both adolescents and adults. She has made Mentalization-Based Therapy (MBT) a cornerstone of Brooklyn Minds treatment plans and company culture. The mentalization team-based model is designed specifically for clients who have otherwise been deemed “hard to reach, hard to teach” and living at the edge of care. With Dr. MacMillan’s guidance and vision, we have had immense progress in reaching previously underserved segments of the community, a trend that continues as we expand. As Brooklyn Minds continues to grow, Dr. MacMillan actively seeks new and creative ways to utilize cutting-edge technology to improve patient outcomes and allow our practice to expand further and serve a wider array of clients spanning the country while maintaining a quality of care and welcoming culture that Brooklyn Minds has come to be known for.

Panelist, Lucia Huang

Co-Founder & CEO, Osmind

Lucia is co-founder and CEO of Osmind. Prior to Osmind, she led business and operations at Verge Genomics, invested in innovative healthcare technology companies at Warburg Pincus, and advised life sciences companies in investment banking. Lucia graduated Yale with a B.S. in Chemistry and earned an MBA at Stanford. Lucia is passionate about mental health and has devoted her career to improving healthcare, from life sciences to new technology innovation.

Panel 3 - "Road to Monetization"

The majority of psychedelic companies today operate under the expectation of some type of future regulatory approval of psychedelics-based therapy. While this creates forward projections of large revenues post legalization, companies should also begin integrating short term revenue generating solutions within their business plan. This panel will explore the options the current legal landscape offers for short term revenue generation, such as ancillary services, legal related products, and more.

Moderator, Tom Zuber

Managing Partner, Zuber Lawler

Tom Zuber is a founder and the Managing Partner of Zuber Lawler.  Tom is the relationship partner for some 10 Fortune 500 Company clients of the firm, as well as funds and government entities.  He has also represented leading “plant” medicines companies for 15 years.  Zuber Lawler as a firm manages the highest-stakes matters of a large percentage of the biggest brands in global cannabis and psychedelics.  Tom is a founder of the international psychedelics consulting company Psychedelics Go and the magazine Psychedelia, and he sits on the board of the Psychedelics Medicine Coalition.  Tom is also a founder of the international cannabis consulting company Global Go. He earned a J.D. degree Columbia Law School, a master’s in public policy degree from Harvard University, and a biomedical engineering degree from Rutgers University, where he graduated with highest honors.

Panelist, Greg McKee

Chairman & CEO, TRYP Therapeutics

Mr. McKee has more than 20 years of biotechnology, life sciences management and leadership and venture investment experience. Before joining Tryp, he founded Torrent Ventures, an early stage digital health and medical technology venture fund, and served as chief executive officer of CONNECT, the largest Southern California start-up accelerator creating and scaling innovative life sciences and technology companies. Prior to CONNECT he was chairman, president and chief executive officer publicly traded Nventa Biopharmacueticals which successfully merged with Akela Pharma. Additionally, he has held senior management roles at Genzyme Corporation, which was acquired by Sanofi for $22 billion. Mr. McKee has lived and worked in Tokyo, Japan for seven years managing a $550M investment portfolio at the Mizuho Group and as an investment banker with UBS. He was also senior advisor to the Former Minister of Foreign Affairs of Japan. Additionally, Mr. McKee lived and worked in Singapore for 2 years, managing Genzyme’s business units in South East Asia and mainland China.Mr. McKee earned a B.A. in Economics from the University of Washington, a M.A. in International Studies from The Joseph H. Lauder Institute and an M.B.A from the Wharton School, at the University of Pennsylvania. He has been a member of Young President’s Organization (YPO) since 2006.

Panelist, Kazi "Zayn" Hassan, MD

Cofounder & CMO, NueLife Health

Dr. Kazi (Zayn) Hassan specializes in Physical Medicine and Rehabilitation after training at Jackson Health Systems/University of Miami/Miami VA after graduating from Tufts University School of Medicine in Boston, MA. His current focus is in the field of integrative psychiatry, particularly in the field of psychedelic therapies. His goal is to translate clinical research and apply an analytical framework to help providers drive better patient outcomes through technology and data science. He is a member of the American Society of Ketamine Physicians, Ketamine Psychotherapy Associates, Integrative Psychiatric Institute Fellowship Program, Psychedelic Assisted Therapy Program (IPI), and Ketamine Training Center. He strives to attain truly transformative and sustainable changes that promote overall brain health and mental wellness.

Panelist, Kelsey Ramsden

Co-Founder & CMO, Mind Cure Health Inc.

Kelsey has over 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple 8-figure businesses from the ground up and has twice been named Canada’s Top Female Entrepreneur. Kelsey also serves on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member teaching Design Thinking. Kelsey holds an MBA from the Richard Ivey School of Business at the University of Western Ontario. She is an accomplished keynote speaker and published author.

Panelist, Robert Roscow, M.A.

Director & Chief Scientific Officer, Mydecine

Robert Roscow is the Chief Scientific Officer of Mydecine. As a highly educated geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. The last two companies that Mr. Roscow applied his innovations to were Canopy Growth and Ebbu, where he ran their genetics divisions. Mr. Roscow has already leveraged expertise in genomics, evolution, and molecular biology to maximize the industrial production of cannabinoids and their use in a pharmacological context. This work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of fungi.

Psychedelics Now Virtual Conference

June 23rd, 2021

Hosted By:

Panel 1

“Clearing the Haze – What’s Legal Today?”

10AM-11AM PT

Panel 2

“Ketamine Clinics Dos and Don’ts”

11:30AM-12:30PM PT

Panel 3

“Interested in Investing in Pyschedelics?”




Host - Paul Rosen

Executive Chairman, Psychedelics Go

Paul Rosen is a noted career entrepreneur, management consultant and public speaker.
Paul was a co-founder of PharmaCan Capital Corp. doing business as The Cronos Group (NASDAQ: CRON; TSX: CRON) and served as its first President and CEO. Paul has held board positions with a number of publicly traded cannabis companies, and serves as the Executive Chairman of Global Go, a leading advisory focused on the global regulated cannabis and psychedelic industries. Paul currently serves as interim CEO of 1933 Industries, a Las Vegas based vertically integrated cannabis operator. Paul is also a Director at Delic Holdings Inc. (DELC:CNSX), a leader in the nascent and growing space of psychedelic wellness.

Panel 1 - "Clearing the Haze - What's Legal Today"

Over the past two years, North America has seen a number of jurisdictions take real steps towards decriminalizing and legalizing psychedelic substances, most notably psilocybin. From successful voter initiatives in Denver, CO, Washington, DC, and Santa Cruz, CA to successful statewide measures in Oregon, psychedelics are on its way towards legalization. In 2019 the FDA has approved treatment for ketamine-based nasal spray Spravato and granted “breakthrough therapy designation” to two psilocybin formulas for depression treatment. This panel will focus on clarifying the legal landscape so that both public and private companies can understand the market opportunities associated with government-approved psychedelics.

Moderator, Dr. Jayashree Mitra

Partner, Zuber Lawler

Dr. Jayashree Mitra focuses on patent litigation, IPR and PGR proceedings, and trade secret matters. Dr. Mitra has litigated drug patents for one of the biggest pharmaceutical companies in the world. She has experience successfully litigating a diverse range of products in the pharmaceutical and cannabis industries, and is increasingly focused on the future landscape of litigation in the psychedelics space. She also has extensive experience advising clients in relation to psychedelics and cannabis related technology, including as to developing their intellectual property portfolios, and navigating the complex regulatory pathways before the FDA. She works in federal courts and before the International Trade Commission. She earned a Ph.D. in Pharmacology from Yale University and her J.D. from Northwestern University School of Law, where she was a member of the Law Review.

Panelist, Tim Moore


Tim Moore is the former CEO of Green Growth Brands, leading the company from its IPO through to January 2019, reaching a nearly billion dollar market cap. Prior to that, Mr. Moore had a successful career in packaged goods where he spent 18 years at Clorox, with the last eight serving as president. Before that, he spent seven years at Brita as managing director of the North America foodservice and retail businesses.


Mr. Moore joined HAVN Life in 2020 and is now leveraging his past leadership experience in the cannabis industry to create an effective path to success for HAVN Life, whose mission is to use evidence-informed research to unlock human performance and help to define and standardize the future of modern medicine.

Panelist, Timothy Ko

CEO, Entheon Biomedical

Timothy has a background of leading private ventures in the Investor Relations, Retail and Technology sectors. With a professional emphasis on disruptive technologies that challenge the status quo, Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of current mental health and addiction treatment options, and through his exposure to psychedelics, which he credits with saving his life.

Panelist, Hadas Alterman

Founding Partner,Plant Medicine Law Group LLP

Hadas is an Israeli-American attorney, born in Jerusalem and raised in the San Francisco Bay Area. She has a J.D. from Berkeley Law and a B.A. in Community Studies/Agriculture & Social Justice from the University of California at Santa Cruz. Hadas advises companies on matters of regulatory compliance, policy advocacy, risk management, strategic planning, revenue models, corporate governance, and dispute resolution. Prior to founding PMLG, she worked with a leading cannabis law firm in San Francisco. Hadas has led clients through successful cannabis license applications in California, Maryland, Ohio, and Pennsylvania; served as counsel to equity applicants in Oakland and San Francisco, and works with legacy growers in the Emerald Triangle. Hadas is a former restorative justice practitioner and community organizer dedicated to using the law to expand equitable access to plant medicine. Hadas was the Policy Director of NYMHA, an organization that she co-founded that successfully lobbied for the introduction of a New York bill to decriminalize psilocybin by statute, and is a Board Member of the Psychedelic Bar Association. She also serves on the Equity Subcommittee of the Oregon Psilocybin Advisory Board.

Panelist, David Wood, PhD

Chief Legal Officer & General Counsel, Psygen Industries Ltd.

David Wood is a lawyer and patent agent with a PhD in Structural Biochemistry from the University of Saskatchewan. He is an expert
in intellectual property law and regulatory law (controlled substances, cannabis and drug product commercialization).

Broadening regulated access to psychedelics is my top professional priority and my top personal priority outside of my family. I am grateful and fortunate to be in a position to focus my career on advancing this priority. In my role as Chief Legal Officer and General Counsel to Psygen Industries Ltd., I am privileged to work as part of a team of effective and motivated professionals. Through Psygen’s contract manufacturing services and research, we are motivated to bring back LSD, advance understanding of the therapeutic possibilities presented by psychedelics and contribute to the global supply chain for these powerful compounds.

My understanding of intellectual property, controlled substance regulations and drug product commercialization dovetails with my understanding of organic chemistry and biochemistry to bring significant value in work with psychedelics. Twelve years of experience working at Canada’s largest national law firm, including four years of co-chairing a psychedelics and cannabis focus group, have provided me with the experience and perspective to provide high-impact and effective legal advice in this specialized and dynamic space.

Panel 2 - "Ketamine Clinics Dos and Don'ts"

Ketamine, one of the world’s most commonly used drugs for more than 50 years, has recently evolved as what can only be described as a phenomenon in treating severe depression and other mental health disorders. A recent boom in the proliferation of ketamine infusion clinics opening up across North America has left many wondering what these means for behaviorial healthcare treatment and how to succeeed in this new industry. This panel will focus on the logistics of opening and operating a ketamine clinic given the complex interplay of federal, state, and local laws.

Moderator, Tegan Joan

Founder, Acid-Channel Inc.

Experienced Chief Executive Officer with a demonstrated history of working in different areas of development. Skilled in ESG and Corporate Social Responsibility, Sustainable Business, Management, Community Engagement, and Policy Analysis. Strong business development professional with a Master of Science (MSc) focused in Integrated Studies (Carbon Accounting, Corporate Social Responsibility and Climate Policy Design) from The University of British Columbia.

Panelist, Ali Mohammed, PhD

CEO, Lyte Medical

Our focus at Lyte Medical is taking the stress out of having to physically see a doctor. Our Telemedicine platform allows patients to speak to a doctor from the comfort of their own home. At Lyte Medical we aim to make our patients interaction with health care professionals as simple as possible. Our technology driven clinic focuses on patients needs and strives to enhance their overall medical experience.

At Lyte Clinics we strive to be the best Health Canada approved telemedicine clinic in Canada. Appointments are completely covered with your provincial health card, no doctor referral is needed and we are available in almost every Province. Our quick and easy system allows you to fill out your intake forms, see the doctor, and order from on of our 24 Licensed Producers of your choosing all from the comfort of your own home. Lyte has helped thousands of patients and our goal has always been to improve the lives of our patients with high- quality patient care, education and service that is readily accessible. Lyte is committed to continuously enrich people’s lives so they can live a happy and healthy life.

Panelist, Matt Stang

CEO, Delic Corp.

Matt Stang was an Owner and Operator of High Times, the most recognized brand in Cannabis, for 17 years prior to its sale to a private equity fund, and during that time he helped legalize Cannabis in multiple states, launched the Cannabis Cup in America, and helped build the legal cannabis industry. For almost 20 years he has met and interacted with all corners within the cannabis community. As one of the most connected people in the Alternative Drug space, he helped found DELIC two years ago as one of the first psychedelic corporations. His expertise in business includes marketing, branding, business development and product viability.

Panelist, Ronan Levy

Co-Founder & Executive Chairman, Field Trip

Believing that you should never hesitate to trade your cow for a handful of magic beans, Ronan has built a career out of doing things that others say cannot be done. Ronan started his career as a securities lawyer at Blake, Cassels & Graydon LLP but left that after realizing he was much too creative for the profession of law. Since then, Ronan has helped launch business across a number of industries from gold, to cannabis, and, most recently, in psychedelics where he is a Co-founder and the Executive Chairman of Field Trip Health Ltd. (TSX: FTRP, OTCQX:FTRPF).

Panelist, Kazi Zayn Hassan, MD

Chief Medical Officer, Nue Life Health

Dr. Kazi (Zayn) Hassan specializes in Physical Medicine and Rehabilitation after training at Jackson Health Systems/University of Miami/Miami VA after graduating from Tufts University School of Medicine in Boston, MA. His current focus is in the field of integrative psychiatry, particularly in the field of psychedelic therapies.

His goal is to translate clinical research and apply an analytical framework to help providers drive better patient outcomes through technology and data science. He is a member of the American Society of Ketamine Physicians, Integrative Psychiatric Institute Fellowship Program, Psychedelic Assisted Therapy Program (IPI), and Ketamine Training Center. He strives to attain truly transformative and sustainable changes that promote overall brain health and mental wellness.

Panel 3 - "Interested in Investing in Psychedelics?"

Psychedelics are on the precipice of legalization and family offices and high-net worthy individual investors are eyeing early stage investments in this new market. In North America, dozens of companies have already gone public, with 25 companies listed on the Canadian Stock Exchange. On this panel we will be discussing identifying opportunities and avoiding pitfalls when investing in psychedelics.

Moderator, Anna Serin

Director of Listings Development, Canadian Securities Exchange

Ms. Serin has 20 years of experience in securities and corporate finance. She has an unwavering passion, perseverance and commitment to the capital markets and investment industry. She started her education in Business and Psychology, accomplished her brokerage and wealth management designations with honours and real estate licensing via Sauder School of Business.
Anna has worked with public companies providing all of their corporate and restructuring needs in the small cap space. She has aided companies with financings, financial reporting and maintenance, debt settlement and negotiations as well as all public disclosure and filings. She joined as Director of Listings Development with the Canadian Securities Exchange in 2016 and focuses on many areas of business and professional development initiatives within the community. Ms. Serin sits on the Corporate Finance committee with the BC Securities Commission as well as the Marketing and Communication Committee with AMEBC.

Panelist, Greg Benson

CEO, Releave Therapeutics

Greg currently leads ReLeave Therapeutics as CEO, with responsibility for business growth and ongoing efforts with international expansion into emerging markets with respect to medical cannabis and psychedelics.

In his previous role with one of Canada’s first and largest medical cannabis clinic companies, Natural Health Services, he served as Senior Vice President working closely with the President. Benson’s leadership expanded beyond the typical boundaries of an executive where he has driven many strategic initiatives having a positive impact on multiple business areas.

Before joining Natural Health Services in 2016, Benson served as President/Founder of Health Matters International, where he grew revenues to $21 million globally over a 10-year period. He was responsible for building, growing and maintaining a successful International Health Care company with divisions in pharmaceuticals, OTC products, international medical surgeries, diabetes and cancer products. Greg developed an international pharmacy platform with partners in Italy, London UK, India, New Zealand, Australia, USA, South Africa and Canada where patients were offered a choice where to receive their prescription medication. Expanding into medical travel, Benson contracted with hospitals in Panama, Costa Rica, Los Cabo and Barbados where they offered medical surgeries and procedures in collaboration with the patient’s local physician.

Benson’s shared passion for healthcare and business started when he held various positions with tier 1 pharmaceutical companies such as Pfizer and AstraZeneca. Over his 8 years in the pharmaceutical industry, he learned many skills and became very knowledgeable in the global healthcare industry which led him to start his own International Healthcare Company.

Panelist, Harrison Keenan

Senior VP, CannAccord Genuity

Harrison Keenan has worked in the financial services industry since 1998. Providing timely investment advice, complementary financial planning and excellent customer service is his pledge to clients.
After entering the financial industry in 1998 as an analyst, he quickly moved to develop his own client base as an Investment Advisor.
He believes the client must always come first, and every client is unique. Harrison works hard to understand what each individual needs and to tailor solutions that meets their unique criteria.
An avid golfer, ultimate Frisbee player, competitive runner and cyclist, Harrison keeps physically busy every chance he can get. He is also a proud supporter of UTS, Care-Alive, St Michael’s Hospital, JDRF, UWGT, and “Movember”, among other causes.

Panelist, Josh Lawler

Partner, Zuber Lawler

Josh Lawler handles M&A, finance and corporate matters for private equity groups, and public and private companies, both domestically and internationally. He has also represented leading cannabis companies for over 14 years, and has more recently been at the cutting edge of legal work in the psychedelics space as well. Josh has extensive experience with complex deals relating to alternative medicines. He counsels cannabis and psychedelics companies on acquisitions and mergers, and post-acquisition and post-merger integration. His work with both leading cannabis, psychedelics, and leading blockchain companies positions him perhaps uniquely well to advise as to the intersection of plant, fungus, and blockchain technologies. Josh holds a B.S. from Duke University, and is a cum laude graduate of Northwestern University School of Law, and earned his B.S. and B.A. from Duke University.

Panelist, Rick Palmon

Founder, NCG Group

Rick Palmon is the founder of NCG Group, a boutique investment firm specializing in psychedelics. NCG Group focuses on private and public investments, institutional advisory services, and charitable initiatives. Mr. Palmon has enjoyed a 20 year career as a cross-asset portfolio manager, most recently with Susquehanna International Group (SIG). Prior to SIG, Mr. Palmon co-founded PAMLI Capital and managed relative value portfolios at Deutsche Bank London, UBS and Societe Generale. Mr. Palmon graduated from MIT with a BS in Mathematics and is a CFA charter holder. He is passionate about making psychedelic medicine accessible, attending and deejaying live music, Brooklyn Nets basketball and skiing.

Event Video Library

Psychedelics Now Webinar

December 8th, 2021

The FDA and Psychedelics – Where Are We Today?

Ketamine and the Insurance Quagmire

The Road To Monetization

Psychedelics Now Webinar

June 23rd, 2021

Clearing the Haze – What’s Legal Today

Ketamine Clinics Dos and Don’s

Interested in Investing in Psychedelics?